PT UBC Medical Indonesia Tbk
IDX:LABS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PT UBC Medical Indonesia Tbk
Total Current Assets
PT UBC Medical Indonesia Tbk
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
PT UBC Medical Indonesia Tbk
IDX:LABS
|
Total Current Assets
Rp159B
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dosni Roha Indonesia Tbk PT
IDX:ZBRA
|
Total Current Assets
Rp2.3T
|
CAGR 3-Years
-4%
|
CAGR 5-Years
332%
|
CAGR 10-Years
73%
|
|
|
Enseval Putera Megatrading Tbk PT
IDX:EPMT
|
Total Current Assets
Rp11.2T
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
I
|
Itama Ranoraya PT
IDX:IRRA
|
Total Current Assets
Rp1.7T
|
CAGR 3-Years
51%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Millennium Pharmacon International Tbk PT
IDX:SDPC
|
Total Current Assets
Rp1.7T
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
PT UBC Medical Indonesia Tbk
Glance View
PT UBC Medical Indonesia Tbk is a ID-based company operating in Health Care Providers & Services industry. The company is headquartered in Jakarta Timur, Dki Jakarta and currently employs 64 full-time employees. The company went IPO on 2024-07-10. PT UBC Medical Indonesia Tbk is an Indonesia-based medical diagnostic company. The firm provides affordable medical diagnostic tests and instruments for the Indonesian healthcare market. The firm operates through two segments: Medical disposable and consumables, and Diagnostic and equipment. The company offers various products to detect and diagnose various diseases, such as tuberculosis, cervical cancer, newborn screening, COVID-19, health risk screening with artificial intelligence (AI) and molecular systems. Its products include NeoMoDX Molecular System, Airdoc, QIAstat-DX Analyzer, Care HPV System, Hybrid Capture 2 - HPV DNA Test, Revvity SARS-COV-2 RT PCR, Geneproof SARS-COV-2 PCR KIT, Quantiferon TB Gold Plus, Genoscholar, Ina TB, GSP Neonatal Kit, Delfia Neonatal Kit, Neonatal Sampling Paper and Victor2 D.
See Also
What is PT UBC Medical Indonesia Tbk's Total Current Assets?
Total Current Assets
159B
IDR
Based on the financial report for Dec 31, 2024, PT UBC Medical Indonesia Tbk's Total Current Assets amounts to 159B IDR.
What is PT UBC Medical Indonesia Tbk's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
39%
Over the last year, the Total Current Assets growth was 43%. The average annual Total Current Assets growth rates for PT UBC Medical Indonesia Tbk have been 39% over the past three years .
